Skip to main content
. 2022 Sep 13;12(12):2856–2879. doi: 10.1158/2159-8290.CD-22-0603

Figure 2.

Figure 2. Mutational signatures. A, The number of SNVs and proportion of SBS signatures in each melanoma subtype. If the etiology for a signature is known, this is listed in parentheses after the signature name. HRD, homologous repair defect. B, The contribution of UVR signature and tumor primary site in non-CM tumors that have a UVR signature present (>0% UVR contribution). C, The contribution of SBS38 in each subtype in tumors that have an SBS38 signature present (>0% SBS38 contribution). D, Difference per tumor between the percentage of early and late clonal mutations attributed to UVR or SBS38 mutational signatures. E, Difference per tumor between the percentage of clonal and subclonal mutations attributed to UVR or SBS38 mutational signatures.

Mutational signatures. A, The number of SNVs and proportion of SBS signatures in each melanoma subtype. If the etiology for a signature is known, this is listed in parentheses after the signature name. HRD, homologous repair defect. B, The contribution of UVR signature and tumor primary site in non-CM tumors that have a UVR signature present (>0% UVR contribution). C, The contribution of SBS38 in each subtype in tumors that have an SBS38 signature present (>0% SBS38 contribution). D, Difference per tumor between the percentage of early and late clonal mutations attributed to UVR or SBS38 mutational signatures. E, Difference per tumor between the percentage of clonal and subclonal mutations attributed to UVR or SBS38 mutational signatures.